Sagimet Biosciences Inc.
SGMT
$7.11
-$0.24-3.27%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -27.94% | -174.19% | -98.76% | -130.11% | -19.65% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.02% | 62.13% | 12.39% | -44.04% | -7.19% |
| Change in Net Operating Assets | -108.46% | 1,571.82% | 1,407.86% | -1,123.17% | 7,485.00% |
| Cash from Operations | -61.54% | -134.15% | -55.64% | -404.49% | 1.50% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 82.32% | 13.77% | 150.20% | -- | -687.16% |
| Cash from Investing | 82.32% | 13.77% | 150.20% | -- | -687.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -100.00% | 97.03% |
| Cash from Financing | 103.70% | -- | -- | -100.00% | 97.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 72.30% | -110.94% | 95.60% | -122.73% | -1,409.85% |